Self-Organizing Nanostructures (SONS) as therapeutic nanoreactors.

Project Details


In today's society cancer is one of the most common diseases. Approximately 1.3 million new cases have been recorded in 2003 in the US alone (ACS). For most patients an intervention with anticancer drugs in necessary, invariable causing systemic toxicity. To avoid this, strategies for targeted drug delivery or selective local activation of prodrugs at the tumor site are being developed. Unfortunately, most prodrug-activating strategies, such as ADEPT, ADAPT and GDEPT, suffer from disadvantages such as immunogenicity, little bystander effect and ineffecient delivery.
To overcome these setbacks we are developing a new system for selective activation of prodrugs in which the prodrug-activating enzyme is encapsulated in nanometer-sized vesicles constructed of PMOXA-PDMS-PMOXA triblock copolymers. To allow diffusion of a prodrug into the vesicle, it is permeabilised by incorporating the bacterial porines OmpF or Tsx, thereby creating a functional nanoreactor. These nanoreactors will be equipped with tupor-specific camel antibodies. The prodrug activating enzyme used here is nucleoside hydrolase (NH) of T. vivax.
Effective start/end date1/01/0731/12/07


  • biology

Flemish discipline codes

  • Biological sciences